Premium
Analysis of HBV genotype, drug resistant mutations, and pre‐core/basal core promoter mutations in Korean patients with acute hepatitis B
Author(s) -
Lee Jong Ho,
Hong Sun Pyo,
Jang Eun Sun,
Park Sang Jong,
Hwang Seong Gyu,
Kang SookKyoung,
Jeong SookHyang
Publication year - 2015
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.24148
Subject(s) - adefovir , entecavir , lamivudine , virology , hepatitis b virus , genotype , hepatitis b , drug resistance , orthohepadnavirus , genotyping , medicine , hepadnaviridae , biology , virus , gene , genetics
Acute hepatitis B, caused by hepatitis B virus (HBV) strains with drug resistant mutations or pre‐core/basal core promoter (PC/BCP) mutations, is a public health concern, because this infection is often associated with poor disease outcome or difficulty in therapeutic choice. The HBV genotype, the prevalence of drug resistant mutations, and PC/BCP mutations in Korean patients with acute hepatitis B were studied. From 2006 to 2008, 36 patients with acute hepatitis B were enrolled prospectively in four general hospitals. Among them, 20 showed detectable HBV DNA (median value was 4.8 log copies/mL). HBV genotyping and analysis of HBV mutations that conferred resistance against lamivudine, adefovir, or entecavir and of PC/BCP mutations were performed using highly sensitive restriction fragment mass polymorphism (RFMP) analysis. All 20 patients were infected with HBV genotype C, which causes almost all cases of chronic hepatitis B in Korea. No patient showed mutations that conferred resistance against lamivudine (L180M, M204V/I), adefovir (A181T, N236S), or entecavir (I169M, A184T/V, S202I/G, M250V/I/L). However, four patients had BCP mutations, and two had PC mutations. Platelet counts were significantly lower in the four patients with PC/BCP mutations compared to those with wild type. In this study, all acute hepatitis B patients had genotype C HBV strains with no drug resistant mutations. However, 20% showed PC/BCP mutations. This highlights the need for further study on the significance of PC/BCP mutations. J. Med. Virol. 87:993–998, 2015 . © 2015 Wiley Periodicals, Inc.